Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Claudia Jambrina"'
Autor:
Jordi Rodó, Miquel Garcia, Estefania Casana, Sergio Muñoz, Claudia Jambrina, Victor Sacristan, Sylvie Franckhauser, Ignasi Grass, Veronica Jimenez, Fatima Bosch
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-13 (2023)
Abstract Obesity and type 2 diabetes are two closely related diseases representing a serious threat worldwide. An increase in metabolic rate through enhancement of non-shivering thermogenesis in adipose tissue may represent a potential therapeutic st
Externí odkaz:
https://doaj.org/article/fef37098d6ab46d092022796ee2c6d0a
Autor:
Estefania Casana, Veronica Jimenez, Claudia Jambrina, Victor Sacristan, Sergio Muñoz, Jordi Rodo, Ignasi Grass, Miquel Garcia, Cristina Mallol, Xavier León, Alba Casellas, Víctor Sánchez, Sylvie Franckhauser, Tura Ferré, Sara Marcó, Fatima Bosch
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 25, Iss , Pp 190-204 (2022)
Type 2 diabetes, insulin resistance, and obesity are strongly associated and are a major health problem worldwide. Obesity largely results from a sustained imbalance between energy intake and expenditure. Therapeutic approaches targeting metabolic ra
Externí odkaz:
https://doaj.org/article/424459a9f476495e9411067950fe1b43
Autor:
Veronica Jimenez, Claudia Jambrina, Estefania Casana, Victor Sacristan, Sergio Muñoz, Sara Darriba, Jordi Rodó, Cristina Mallol, Miquel Garcia, Xavier León, Sara Marcó, Albert Ribera, Ivet Elias, Alba Casellas, Ignasi Grass, Gemma Elias, Tura Ferré, Sandra Motas, Sylvie Franckhauser, Francisca Mulero, Marc Navarro, Virginia Haurigot, Jesus Ruberte, Fatima Bosch
Publikováno v:
EMBO Molecular Medicine, Vol 10, Iss 8, Pp 1-24 (2018)
Abstract Prevalence of type 2 diabetes (T2D) and obesity is increasing worldwide. Currently available therapies are not suited for all patients in the heterogeneous obese/T2D population, hence the need for novel treatments. Fibroblast growth factor 2
Externí odkaz:
https://doaj.org/article/5049632ea9d54bcabb730fd40ac11d0c
Autor:
Cristina Mallol, Estefania Casana, Veronica Jimenez, Alba Casellas, Virginia Haurigot, Claudia Jambrina, Victor Sacristan, Meritxell Morró, Judith Agudo, Laia Vilà, Fatima Bosch
Publikováno v:
Molecular Metabolism, Vol 6, Iss 7, Pp 664-680 (2017)
Objective: Type 1 diabetes is characterized by autoimmune destruction of β-cells leading to severe insulin deficiency. Although many improvements have been made in recent years, exogenous insulin therapy is still imperfect; new therapeutic approache
Externí odkaz:
https://doaj.org/article/015304f16dce4dd397e4344c025b626e
Autor:
Sylvie Franckhauser, Victor Sacristan, Estefania Casana, Cristina Mallol, Xavier León, Miquel Garcia, Claudia Jambrina, Sergio Muñoz, Veronica Jimenez, Fatima Bosch, Jordi Rodó
Publikováno v:
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Universitat Autònoma de Barcelona
Altres ajuts: ICREA Academia Award Background/objectives: During obesity, hypertrophic enlargement of white adipose tissue (WAT) promotes ectopic lipid deposition and development of insulin resistance. In contrast, WAT hyperplasia is associated with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22ace4b0f8ed5c5cb97cc3669a8c1b45
https://ddd.uab.cat/record/239890
https://ddd.uab.cat/record/239890
Autor:
Victor Sacristan, Laia Vilà, Fatima Bosch, Alba Casellas, Meritxell Morró, Estefania Casana, Claudia Jambrina, Cristina Mallol, Judith Agudo, Virginia Haurigot, Veronica Jimenez
Publikováno v:
Molecular Metabolism, Vol 6, Iss 7, Pp 664-680 (2017)
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Objective Type 1 diabetes is characterized by autoimmune destruction of β-cells leading to severe insulin deficiency. Although many improvements have been made in recent years, exogenous insulin therapy is still imperfect; new therapeutic approaches
Autor:
Miquel Garcia, Sylvie Franckhauser, Veronica Jimenez, Victor Sacristán Fraile, Sara Darriba, Xavier León, Ignasi Grass, Sergio Muñoz, Cristina Mallol, Estefania Casana Lorente, Fatima Bosch, Jordi Rodó, Claudia Jambrina Pallarés
Publikováno v:
Diabetes. 67
Obesity and type 2 diabetes are strongly associated and a major health problem because of their alarmingly growing prevalence worldwide. The hypertrophic expansion of white adipose tissue (WAT) promotes ectopic fat accumulation and development of ins
Autor:
Sergio Muñoz, Fatima Bosch, Cristina Mallol, Claudia Jambrina, Tura Ferre, Sylvie Franckhauser, Veronica Jimenez, Ivet Elias, Estefania Casana, Albert Ribera
Publikováno v:
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Diabetes
Universitat Autònoma de Barcelona
Diabetes
Adipose tissue is pivotal in the regulation of energy homeostasis through the balance of energy storage and expenditure and as an endocrine organ. An inadequate mass and/or alterations in the metabolic and endocrine functions of adipose tissue underl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c96d8111db006f09101c558e966a0c6
https://ddd.uab.cat/record/184947
https://ddd.uab.cat/record/184947
Autor:
Veronica Jimenez, Gemma Elias, Tura Ferre, Sara Darriba, Virginia Haurigot, Fatima Bosch, Miquel Garcia, Estefania Casana, Jordi Rodó, Sergio Muñoz, Sandra Motas, Alba Casellas, Claudia Jambrina, Ignasi Grass, Albert Ribera, Sylvie Franckhauser, Francisca Mulero, Marc Navarro, Victor Sacristan, Sara Marcó, Cristina Mallol, Xavier León, Jesús Ruberte, Ivet Elias
Publikováno v:
EMBO Molecular Medicine
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Repisalud
Instituto de Salud Carlos III (ISCIII)
EMBO Molecular Medicine, Vol 10, Iss 8, Pp n/a-n/a (2018)
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Repisalud
Instituto de Salud Carlos III (ISCIII)
EMBO Molecular Medicine, Vol 10, Iss 8, Pp n/a-n/a (2018)
Prevalence of type 2 diabetes (T2D) and obesity is increasing worldwide. Currently available therapies are not suited for all patients in the heterogeneous obese/T2D population, hence the need for novel treatments. Fibroblast growth factor 21 (FGF21)